Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

From Lab Innovation to Life-Saving Therapies: Gene Editing Therapeutics Market Poised to Hit US$ 6.26 Billion by 2032, Expanding at a 147.20% CAGR Driven by Rap…

Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...

Portable CRISPR-based test detects four STIs, including syphilis, in under an hour

Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...

Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

After a baby became the world's first CRISPR gene editing therapy patient, CHOP wants to expand treatment to others

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...
BioSpace

Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...

T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors

Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiationSAN FRANCISCO and BERLIN, ...

Should you buy shares of CRISPR Therapeutics in February?

The company could finally be ready to deliver on years of promise.
STAT

Prime Medicine to seek approval for gene-editing treatment after two-patient trial

Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

A common CRISPR platform enables comparative studies of multicellularity in social amoebae

A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a CRISPR genome editing technique that enables comparative analysis of the ...
Fierce Biotech

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

Why Is CRISPR Therapeutics Stock Surging Thursday?

CRISPR Therapeutics AG CRSP shares jumped on Thursday, building on its Feb. 13 earnings report that showed growing momentum for its lead gene therapy and a deepening pipeline. Casgevy Revenue Casgevy, ...